Patents by Inventor Donald F. Weaver
Donald F. Weaver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11568956Abstract: Methods for identifying compounds that are inhibitors or are likely to be inhibitors of amyloid protein aggregation, as well as three-dimensional, non-crystallographic models (i.e. “pseudo-crystal structures”) of amyloid aggregation utilized in the methods, are described. Means for creating the three-dimensional, non-crystallographic models (i.e. “pseudo-crystal structures”) of amyloid aggregation are also described.Type: GrantFiled: October 26, 2018Date of Patent: January 31, 2023Assignee: Treventis CorporationInventors: Christopher J. Barden, Michael D. Carter, Donald F. Weaver
-
Publication number: 20200369653Abstract: A compound 5-(2,5-bis(4-chloro-2-isopropylphenyl)thiophen-3-yl)-1H-tetrazole, methods for the manufacture of said compound, topical compositions comprising said compound and methods of use thereof in the topical treatment of infections caused by pathogenic bacteria as a wound site.Type: ApplicationFiled: December 10, 2018Publication date: November 26, 2020Inventors: Fan Wu, Christopher R. McMaster, Donald F. Weaver
-
Publication number: 20190050526Abstract: Methods for identifying compounds that are inhibitors or are likely to be inhibitors of amyloid protein aggregation, as well as three-dimensional, non-crystallographic models (i.e. “pseudo-crystal structures”) of amyloid aggregation utilized in the methods, are described. Means for creating the three-dimensional, non-crystallographic models (i.e. “pseudo-crystal structures”) of amyloid aggregation are also described.Type: ApplicationFiled: October 26, 2018Publication date: February 14, 2019Applicant: Treventis CorporationInventors: Christopher J. Barden, Michael D. Carter, Donald F. Weaver
-
Publication number: 20160283652Abstract: Methods for identifying compounds that are inhibitors or are likely to be inhibitors of amyloid protein aggregation, as well as three-dimensional, non-crystallographic models (i.e. “pseudo-crystal structures”) of amyloid aggregation utilized in the methods, are described. Means for creating the three-dimensional, non-crystallographic models (i.e. “pseudo-crystal structures”) of amyloid aggregation are also described.Type: ApplicationFiled: May 16, 2016Publication date: September 29, 2016Applicant: Treventis CorporationInventors: Christopher J. BARDEN, Michael D. Carter, Donald F. Weaver
-
Patent number: 9339227Abstract: A method for analysis of the extent of conscious awareness and likelihood of recovery of a patient includes the steps of applying to the patient a sensory stimulus sequence which is typically auditory; carrying out an EEG to generate waveform signals to record changes in the electromagnetic fields generated by the patient's neural activity; using software provided in a processor to process the waveform signals in order to locate waveform peaks, identify the event-related potential (ERP) components obtained in the waveform and to obtain quantitative measures of those components; and using the software to generate and communicate scores indicative of the extent of conscious awareness and likelihood of recovery of the patient.Type: GrantFiled: June 17, 2011Date of Patent: May 17, 2016Assignee: National Research Council of CanadaInventors: Ryan D'arcy, Donald F. Weaver, Sujoy Ghosh Hajra, Careesa Liu, Lauren Sculthorpe-Petley
-
Publication number: 20140357725Abstract: The present application provides terpene analogues of Formula 1 and methods and uses thereof for treating neurological conditions such as pain in general and neuropathic pain specifically. wherein: Y is a C1 to C20 alkylene, C?O, SO, SO2, or absent; X is H, OR1, N—(R2)2, a C1 to C20 alkyl, or a heterocyclyl (for example, heteroaryl), wherein when Y is absent X is not H; R1 is H, a C1 to C20 alkyl, or a CH2-aryl; R2 is independently H, a C1 to C20 alkyl, aryl, OR1, CN or C(?O)—R3; R3 is a substituted or unsubstituted C1 to C20 alkyl, or a aryl; W is H, C1 to C20 alkyl, or aryl; and Z is C1 to C20 alkylene; or a pharmaceutically acceptable isomer, salt or ester thereof. These terpene analogues are useful in treating pain and can also be used to treat other electrical disorders in the central and peripheral nervous system.Type: ApplicationFiled: July 13, 2012Publication date: December 4, 2014Applicant: NEUROQUEST INC.Inventors: Donald F. Weaver, Mark Andrew Reed, Alexander McLellan, Shengguo Sun
-
Publication number: 20130245422Abstract: A method for analysis of the extent of conscious awareness and likelihood of recovery of a patient includes the steps of applying to the patient a sensory stimulus sequence which is typically auditory; carrying out an EEG to generate waveform signals to record changes in the electromagnetic fields generated by the patient's neural activity; using software provided in a processor to process the waveform signals in order to locate waveform peaks, identify the event-related potential (ERP) components obtained in the waveform and to obtain quantitative measures of those components; and using the software to generate and communicate scores indicative of the extent of conscious awareness and likelihood of recovery of the patient.Type: ApplicationFiled: June 17, 2011Publication date: September 19, 2013Applicant: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Ryan D'arcy, Donald F. Weaver, Sujoy Ghosh Hajra, Careesa Liu, Lauren Sculthorpe-Petley
-
Patent number: 8420640Abstract: The present invention is directed to compounds that inhibit amyloid aggregation and methods of treatment therewith.Type: GrantFiled: August 28, 2009Date of Patent: April 16, 2013Assignee: Treventis CorporationInventors: Christopher J. Barden, Michael D. Carter, Mark A. Reed, Donald F. Weaver, Arun Yadav, Shengguo Sun
-
Patent number: 8362066Abstract: The invention is directed to compounds and methods for treating protein folder disorders. In certain embodiments the invention provides compounds and methods for treating neurodegenerative diseases such as Alzheimer's disease, tauopathy, cerebral amyloid angiopathy, Lewy body disease, dementia, Huntington's disease and prion-based spongiform encelopathy. The invention further provides compounds, methods and pharmaceutical compositions for inhibiting tau protein, A? protein or ?-synuclein protein aggregation.Type: GrantFiled: November 19, 2007Date of Patent: January 29, 2013Assignee: Treventis CorporationInventors: Michael D. Carter, Donald F. Weaver, Sheila Marie H. Jacobo, Erhu Lu, Fuye Gao
-
Publication number: 20110218200Abstract: The present invention is directed to compounds that inhibit amyloid aggregation and methods of treatment there-with.Type: ApplicationFiled: August 28, 2009Publication date: September 8, 2011Inventors: Christopher J. Barden, Michael D. Carter, Mark A. Reed, Donald F. Weaver, Arun Yadav, Shengguo Sun
-
Patent number: 7786174Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.Type: GrantFiled: May 22, 2008Date of Patent: August 31, 2010Assignee: Bellus Health (International) LimitedInventors: Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
-
Patent number: 7754761Abstract: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.Type: GrantFiled: February 16, 2007Date of Patent: July 13, 2010Assignee: Bellus Health (International) LimitedInventors: Robert Kisilevsky, Walter A. Szarek, Donald F. Weaver
-
Publication number: 20100144821Abstract: The invention is directed to compounds and methods for treating protein folder disorders. In certain embodiments the invention provides compounds and methods for treating neurodegenerative diseases such as Alzheimer's disease, tauopathy, cerebral amyloid angiopathy, Lewy body disease, dementia, Huntington's disease and prion-based spongiform encelopathy. The invention further provides compounds, methods and pharmaceutical compositions for inhibiting tau protein, A? protein or ?-synuclein protein aggregation.Type: ApplicationFiled: November 19, 2007Publication date: June 10, 2010Applicant: Queen's University at KingstonInventors: Michael D. Carter, Donald F. Weaver, Sheila Marie H. Jacobo, Erhu Lu, Fuye Gao
-
Publication number: 20090215814Abstract: The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTR common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTR comprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lys34 of nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lys95 of nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lys88 of nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lys32 of nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile31, Phe101 and Phe86 of nerve growth factor.Type: ApplicationFiled: April 28, 2009Publication date: August 27, 2009Inventors: Gregory M. Ross, Igor L. Shamovsky, Sandra Marone, Donald F. Weaver, Richard J. Riopelle
-
Patent number: 7501429Abstract: Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent ictogenesis and/or epileptogenesis. Methods for preparing the compounds of the invention are also described.Type: GrantFiled: April 11, 2002Date of Patent: March 10, 2009Assignee: Queen's University at KingstonInventors: Donald F. Weaver, Buhendwa Musole Guillain, John R. Carran, Kathryn Jones
-
Publication number: 20080227767Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.Type: ApplicationFiled: May 22, 2008Publication date: September 18, 2008Applicant: Neurochem (International) LimitedInventors: Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
-
Publication number: 20080221147Abstract: The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTR common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTR comprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lys34 of nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lys95 of nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lys88 of nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lys32 of nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile31, Phe101 and Phe86 of nerve growth factor.Type: ApplicationFiled: April 8, 2008Publication date: September 11, 2008Inventors: Gregory M. Ross, Igor L. Shamovsky, Sandra Marone, Donald F. Weaver, Richard J. Riopelle
-
Patent number: 7393875Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.Type: GrantFiled: May 2, 2003Date of Patent: July 1, 2008Assignee: Neurochem (International) LimitedInventors: Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
-
Patent number: 7153692Abstract: The present invention exploits the discovery that amounts of uracil and thymine metabolites, especially ?-aminoisobutyric acid, in various bodily fluids, especially urine, are correlated with the occurrence of epilepsy when compared to matched control subjects. Analytical and diagnostic protocols, including a novel high performance liquid chromatography system, for use in the invention are disclosed.Type: GrantFiled: April 13, 2005Date of Patent: December 26, 2006Assignee: Queens University at KingstonInventors: Allyson J. Campbell, Donald F. Weaver, Angela P. Lyon, John R. Carran
-
Patent number: 7148352Abstract: The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTR common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTR comprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lys34 of nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lys95 of nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lys88 of nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lys32 of nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile31, Phe101 and Phe86 of nerve growth factor.Type: GrantFiled: August 16, 2002Date of Patent: December 12, 2006Assignee: Queen's University at KingstonInventors: Gregory M. Ross, Igor L. Shamovsky, Sandra Marone, Donald F. Weaver, Richard J. Riopelle